Oxford BioMedica (OXB) has signed an out-licensing deal with Axovant for its Parkinson’s disease (PD) gene therapy AXO-Lenti-PD (previously OXB-102) worth up to $842.5m. Axovant plans to accelerate it rapidly into the clinic, with a Phase I/II dose escalation study in advanced PD patients to be initiated by year end. In addition to OXB’s numerous other partnerships, notably the recently signed Bioverativ deal and the ongoing collaboration with Novartis on its launched CAR-T Kymria
08 Jun 2018
Oxford BioMedica - Golden age for LentiVector as Axovant signs deal
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Oxford BioMedica - Golden age for LentiVector as Axovant signs deal
Oxford BioMedica plc (OXB:LON) | 218 7.6 1.6% | Mkt Cap: 218.3m
- Published:
08 Jun 2018 -
Author:
Dr Daniel Wilkinson -
Pages:
5
Oxford BioMedica (OXB) has signed an out-licensing deal with Axovant for its Parkinson’s disease (PD) gene therapy AXO-Lenti-PD (previously OXB-102) worth up to $842.5m. Axovant plans to accelerate it rapidly into the clinic, with a Phase I/II dose escalation study in advanced PD patients to be initiated by year end. In addition to OXB’s numerous other partnerships, notably the recently signed Bioverativ deal and the ongoing collaboration with Novartis on its launched CAR-T Kymria